Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer

Join us at ASCO GU 2025 for vital education on the latest clinical insights and molecular targets to advance personalized care in bladder cancer

Live Broadcast

1.50 available credits

Information

February 14, 2025

06:00 PM - 08:00 PM PST

Virtual

ENROLL

Details

Presenters

Comments

Overview
Attend our independent satellite symposium at ASCO GU 2025 to explore innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The session will also focus on creating effective, evidence-based treatment plans, sequencing molecularly targeted therapies, and integrating interprofessional protocols for managing adverse events. This collaborative approach will equip attendees with practical insights to enhance treatment outcomes in their patients with bladder cancer.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Chief, Genitourinary Oncology
Yale School of Medicine
New Haven, CT
Dr. Petrylak has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Merck & Company Inc, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis Pharmaceuticals, Seattle Genetics, UroGen
Other: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Eisai, Eli Lilly, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis, Seattle Genetics
Faculty:
Elizabeth R. Plimack, MD, MS, FASCO
Deputy Director, Fox Chase Cancer Center
Professor of Medical Oncology
Temple Health
Philadelphia, PA
Dr. Plimack has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: 3andME, AbbVie, Adaptimmune, Astellas, AstraZeneca, Auro Biosciences, BMS, Eisai, EMD Serono, Flatiron, Merck, Pfizer, SeaGen, Signatera, Synthekine
Evan Y. Yu, MD
Section Head, Medical Oncology
Fred Hutchinson Cancer Center
Professor of Medicine
University of Washington School of Medicine
Seattle, WA
Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, BMS, Janssen, Lantheus, Loxo Oncology, Merck
Research: Bayer, Blue Earth, Dendreon, Lantheus, Merck, Seagen, Oncternal Therapeutics, Tyra Biosciences
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Differentiate molecular targets and their appropriate profiling methodologies in bladder cancer
- Review recent and emerging clinical trial evidence with molecularly targeted and innovatively delivered therapies in bladder cancer
- Develop evidence-based treatment and sequencing plans for molecularly targeted therapies in patients with bladder cancer
- Incorporate interprofessional monitoring and management protocols for adverse events associated with molecularly targeted therapies in patients with bladder cancer
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and urologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with bladder cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-25-002-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Janssen Biotech, Inc., and Pfizer, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Daniel P. Petrylak, MD

Elizabeth Plimack, MD, MS

Evan Y. Yu, MD

Details

Presenters

Comments

Overview
Attend our independent satellite symposium at ASCO GU 2025 to explore innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The session will also focus on creating effective, evidence-based treatment plans, sequencing molecularly targeted therapies, and integrating interprofessional protocols for managing adverse events. This collaborative approach will equip attendees with practical insights to enhance treatment outcomes in their patients with bladder cancer.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Chief, Genitourinary Oncology
Yale School of Medicine
New Haven, CT
Dr. Petrylak has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Merck & Company Inc, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis Pharmaceuticals, Seattle Genetics, UroGen
Other: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Eisai, Eli Lilly, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis, Seattle Genetics
Faculty:
Elizabeth R. Plimack, MD, MS, FASCO
Deputy Director, Fox Chase Cancer Center
Professor of Medical Oncology
Temple Health
Philadelphia, PA
Dr. Plimack has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: 3andME, AbbVie, Adaptimmune, Astellas, AstraZeneca, Auro Biosciences, BMS, Eisai, EMD Serono, Flatiron, Merck, Pfizer, SeaGen, Signatera, Synthekine
Evan Y. Yu, MD
Section Head, Medical Oncology
Fred Hutchinson Cancer Center
Professor of Medicine
University of Washington School of Medicine
Seattle, WA
Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, BMS, Janssen, Lantheus, Loxo Oncology, Merck
Research: Bayer, Blue Earth, Dendreon, Lantheus, Merck, Seagen, Oncternal Therapeutics, Tyra Biosciences
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Differentiate molecular targets and their appropriate profiling methodologies in bladder cancer
- Review recent and emerging clinical trial evidence with molecularly targeted and innovatively delivered therapies in bladder cancer
- Develop evidence-based treatment and sequencing plans for molecularly targeted therapies in patients with bladder cancer
- Incorporate interprofessional monitoring and management protocols for adverse events associated with molecularly targeted therapies in patients with bladder cancer
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and urologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with bladder cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-25-002-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Janssen Biotech, Inc., and Pfizer, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Daniel P. Petrylak, MD

Elizabeth Plimack, MD, MS

Evan Y. Yu, MD

CME/CE Meeting
Treating At-Risk MASH: What Are You Waiting For?
January 11, 2025
Park City, Utah
1.00 credit Learn more
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

Recommended

Title

Share on ReachMD